Cohance Lifesciences Limited has informed the Exchange about sale of assets of clinical research and bio-analytical studies site (CR Bio) of the Company
COHANCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Cohance Lifesciences is selling its standalone Clinical Research and Bio-analytical (CR Bio) unit to Chromo Laboratories India Private Limited for a total consideration of ₹16 crore. The CR Bio unit is described as a non-core legacy asset with limited strategic alignment to the company's main CDMO (contract development and manufacturing) operations. The unit contributed only ₹9.8 crore in revenue during FY2025, which is just 0.82% of standalone revenue (₹1,197.58 crore) and 0.38% of combined post-merger turnover. The agreement was executed on June 20, 2025, with closing expected in Q2 FY2026, subject to customary conditions. The buyer is independent of the promoter group, the deal is at arm's length, and there is no change in the company's shareholding pattern.
For shareholders, this is a small but tidy portfolio cleanup—offloading a non-core, low-contributing unit to sharpen focus on the higher-value CDMO business. Since CR Bio contributes under 1% of revenue, the financial impact is negligible, but the move signals disciplined capital allocation and operational focus post the recent Cohance merger.